Lack of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons이전에 감염된 대규모 집단에서 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 항체 부족Article Published on 2021-11-022022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed antibodies antibody asymptomatic infections black Chain Reaction collected coronavirus coronavirus 2 detectable determine Detroit drug therapy Ethnicity first responders healthcare worker Healthcare workers Hospitalized IgG IgG antibodies IgG antibody Illness severity Immunoglobulin Immunoglobulin G immunology immunosuppressive Immunosuppressive medication immunosuppressive medications infected with SARS-CoV-2 Infection lack less multivariable model New York City obesity participant Person polymerase chain polymerase chain reaction positive predictor proportion ranged remained report respiratory Responder Risk factors RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein seronegative Seronegativity severe acute respiratory syndrome Coronavirus Severe obesity Spike protein Symptom symptom onset symptomatic test result tested therapy weight white [DOI] 10.1093/cid/ciaa1685 PMC 바로가기 [Article Type] Article
Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseasesArticle Published on 2021-11-012022-10-04 Journal: Acta pharmacologica Sinica [Category] SARS, 신약개발, [키워드] activating activity addition alcohol anti-inflammatory activity applied cause caused Cellular responses circulating Colitis Complication contribute disulfiram DSF dysregulated immune response effective Efficacy endotoxin gasdermin D glycoprotein immunosuppressive Infection Inflammation Inflammatory cytokine inflammatory disease inflammatory disorders Inflammatory response inhibitor lactoferrin life-threatening ligands Macrophage macrophage-targeting delivery macrophages multifunctional murine Neutralizing offer organ dysfunction patients pyroptosis Safe Sepsis therapeutic therapeutic effect therapeutic strategy treat Treatment ulcerative colitis various inflammatory disease [DOI] 10.1038/s41401-021-00770-w PMC 바로가기 [Article Type] Article
The Role of HLA Antigens and Steroid Dose on the Course of COVID-19 of Patients After Kidney TransplantationMedicine Published on 2021-11-012022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] acute respiratory syndrome age Analysis Antigen BMI body mass index Coronavirus-2 Course COVID-19 COVID-19 disease Critical determine doses of corticosteroid higher risk HLA HLA class I and class II typing Hospitalization Hospitalized identify Immunosuppression immunosuppressive independent risk factor Infection kidney Kidney transplantation leukocyte men multicenter outcome Patient positive Prednisone Protective protective factor recipient retrospective risk factor role SARS-CoV-2 SARS-CoV-2 positivity selected steroid steroid dose the disease transplantation two subgroup [DOI] 10.3389/fmed.2021.730156 PMC 바로가기 [Article Type] Medicine
Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients신장 이식 수혜자에서 3회 접종 COVID-19 mRNA 백신 요법의 안전성 및 교차 변이 면역원성Article Published on 2021-11-012022-09-11 Journal: EBioMedicine [Category] MERS, SARS, 변종, 진단, [키워드] anti-Spike IgG antibody Antigen BNT162b2 BNT162b2 vaccine Cell cells cellular response Cellular responses COVID-19 COVID-19 vaccine cytokine cytokine production delta variant dose doses explained Frequency Heterologous homologous IFN-γ IFN-γ response IFN-γ responses IgG immunogenicity immunosuppressive immunosuppressive therapy increase interferon kidney Kidney function kidney transplant kidney transplant recipient longitudinal study Mild mRNA mRNA vaccine neutralization activity Neutralizing activity neutralizing antibody Nice University Hospital one patient Patient PBMC PBMCs performed raised reaction Reactions recipient recipients regimen remained Safety second dose Seroconversion seronegative significant increase spike-specific IgG tested therapy Tolerability university Vaccine variants variants of concern variants of concern, kidney transplantation. [DOI] 10.1016/j.ebiom.2021.103679 PMC 바로가기 [Article Type] Article
Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibioticsObservational Study Published on 2021-11-012022-10-05 Journal: Drug development research [Category] 임상, [키워드] accounted addition Antibiotics Black fungus caused corticosteroid treatment COVID-19 COVID-19 case COVID-19 pandemic deaths Diabetic disease dropped drug First wave fungal Fungal infection glucocorticoid High dose Hypoxemia immune immunosuppressive India maintain Mild misuse Mucormycosis neutropenia pathway poor prognosis recorded reported risk factor SARS-CoV-2 second wave Spread stability Steroids Tocilizumab treated uncontrolled [DOI] 10.1002/ddr.21862 PMC 바로가기 [Article Type] Observational Study
COVID-19 progression in kidney transplant recipients: a single-center case series신장 이식 환자의 COVID-19 진행: 단일 센터 사례 시리즈Case Reports Published on 2021-11-012022-09-11 Journal: CEN case reports [Category] SARS, 치료제, [키워드] Acute kidney injury addition Admission AKI Antiviral treatment baseline case sery clinically suspected complications coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 progression Deceased Deterioration develop dose Dyspnea Fever Follow-up Hydroxychloroquine ICU Immunosuppression immunosuppressive immunosuppressive therapy in-hospital mortality Intensive intensive care intensive care unit kidney Kidney disease kidney transplant kidney transplant recipient kidney transplant recipients median median age myalgia Novel coronavirus novel coronavirus disease Occurrence Patient Prednisolone rapid expansion recipient required respiratory infection respiratory status risk risk factor single-center therapy Topic two patients umifenovir underlying disease was increased with COVID-19 [DOI] 10.1007/s13730-021-00584-z PMC 바로가기 [Article Type] Case Reports
Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort StudyArticle Published on 2021-10-302022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] 95% CI age Antibody titer booster booster vaccination chronic hemodialysis patient chronic hemodialysis patients Cohort Control control group controls COVID-19 determine dosage dose Effect effective Factor healthy control Hemodialysis IgG antibody IgG antibody titer IgG titer immunosuppressive Immunosuppressive medication increase in induce Logistic regression analysis Major Neutralizing Neutralizing antibodies Odds ratio offered Older age participant Patient patients Probability Prospective Protective reduced responders response to vaccination Result risk factor risk factors for non-response SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 vaccination second dose Seven Standard the healthy the patient therapy vaccination vaccine doses virus-neutralizing was used were measured [DOI] 10.3390/jcm10215113 PMC 바로가기 [Article Type] Article
Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody TitersArticle Published on 2021-10-212022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Administered administration antibody booster dose cardiovascular disease collected Comparative coronavirus disease COVID-19 COVID-19 vaccine Diseases doses Efficiency IgG IgG titer IgG titers Immunity immunosuppressive induce mechanisms Multivariable regression analysis participant Pfizer-BioNTech positive positively correlated prospective observational cohort Quantitative recipient recipients second dose Sinopharm specific antibody subject supported titer titers Vaccine Vaccines [DOI] 10.3390/vaccines9111223 PMC 바로가기 [Article Type] Article
Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH ProjectArticle Published on 2021-10-122022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] age analyses analyzed Antigen applied BNT162b2 booster vaccination Chronic kidney disease Control Corticosteroid COVID-19 COVID19 determinant Efficacy Factor highest humoral IgG antibody immune response Immunosuppressant immunosuppressants immunosuppressive independent predictor Infection initial IQR kidney transplant recipient kidney transplant recipients longitudinal magnitude median age men mRNA mRNA vaccine mRNA vaccines mRNA-1273 mRNA-1273 vaccine naïve predictor protocol rate of seroconversion Responder response response to vaccination SARS-CoV-2 vaccination second dose Seroconversion seroconversion rate Transplant treated Treatment vaccination Vaccine younger patient [DOI] 10.3390/vaccines9101165 PMC 바로가기 [Article Type] Article
Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)BNT162b2 mRNA SARS-CoV-2 백신의 추가 용량을 2회 백신 용량 후 적절한 체액 반응 없이 신장 이식 수용자에게 투여할 때 면역 억제 감소: 무작위 대조 시험 프로토콜(BECAME 연구)Article Published on 2021-10-112022-09-11 Journal: BMJ Open [Category] SARS, 임상, [키워드] All participant All participants Antibody Response antimetabolite approved BNT162b2 BNT162b2 mRNA BNT162b2 vaccine booster dose calculated consequence control group COVID-19 described dose eligible Endpoint Ethics humoral immunology Immunosuppression immunosuppressive Inadequate intervention group investigator-initiated kidney transplant recipient kidney transplant recipients Local local Ethics Committee mRNA observational study Open-label participant Patient patients Primary outcome prospective observational study protocol Rabin Medical Center randomised controlled randomised controlled trial receive recipients reduction regimen registration number renal Renal transplantation required Result Sample size SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Seropositivity solid organ solid organ transplant submitted T-cell Response tested Trial Vaccination strategy Vaccine vaccine dose written Informed Consent [DOI] 10.1136/bmjopen-2021-055611 PMC 바로가기 [Article Type] Article